Prioritizing Early Referral for TIL Therapy in Advanced Melanoma

Lilit Karapetyan, MD, MS of the Moffitt Cancer Center discusses a critical challenge in the management of advanced melanoma: the timing of referrals for tumor-infiltrating lymphocyte (TIL) therapy. Current literature and clinical practice show that many patients are only considered for TIL therapy after exhausting multiple lines of treatment, including various immunotherapy combinations like nivolumab/relatlimab (Opdualag) or nivolumab (Opdivo)/ipilimumab (Yervoy), targeted therapies, and even traditional chemotherapy. Karapetyan notes that chemotherapy historically yields poor results for these patients, yet providers often wait until every other option is depleted before exploring cellular therapy.

A primary barrier to earlier utilization is the perception of TIL therapy as a highly toxic intervention. This reputation frequently leads community oncologists to delay referral until the patient is in a much later stage of disease. However, Karapetyan argues that this delay can be detrimental. She advocates for a strategic shift toward earlier evaluation, suggesting that patients should be referred for TIL therapy assessment immediately after evidence of progression on their first line of combination immunotherapy. This recommendation for early referral applies to a broad range of patients, including those with BRAF mutations who could receive targeted inhibitors first.

Karapetyan addresses the misconception that many late-line patients are no longer candidates for TIL therapy due to their performance status or previous treatment history. She emphasizes that with modern medical adjustments such as carefully managed lymphodepleting chemotherapy and optimized IL-2 administration, many patients can still successfully undergo the procedure. By initiating the referral process as soon as a patient progresses past the first-line anti-PD-1/LAG3 or anti-PD-1/CTLA-4 combinations, physicians can ensure that their patients have access to this potent immunotherapy while they are still physically robust enough to derive the maximum benefit. Ultimately, the goal is to integrate TIL therapy into the earlier stages of the treatment algorithm rather than reserving it as a final, last-ditch effort.